Cargando…

Losartan-induced Pancreatitis

Drug-induced acute pancreatitis (DIAP) is a rare gastrointestinal condition but well-known in the medical literature. The medications have been classified into four subgroups (Classes I-IV) depending upon the propensity of the cases discussed in the literature, interval time period between drug init...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwar, Shamsuddin M, Aqsa, Anum, Shaukat, Rameez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937474/
https://www.ncbi.nlm.nih.gov/pubmed/31893179
http://dx.doi.org/10.7759/cureus.6253
_version_ 1783483884375113728
author Anwar, Shamsuddin M
Aqsa, Anum
Shaukat, Rameez
author_facet Anwar, Shamsuddin M
Aqsa, Anum
Shaukat, Rameez
author_sort Anwar, Shamsuddin M
collection PubMed
description Drug-induced acute pancreatitis (DIAP) is a rare gastrointestinal condition but well-known in the medical literature. The medications have been classified into four subgroups (Classes I-IV) depending upon the propensity of the cases discussed in the literature, interval time period between drug initiation to pancreatitis, and reaction to the drug with reintroduction. Our clinical case is one such example where losartan was described as the agent of recurrent pancreatitis after excluding all other possible causes with laboratory and imaging studies.
format Online
Article
Text
id pubmed-6937474
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-69374742019-12-31 Losartan-induced Pancreatitis Anwar, Shamsuddin M Aqsa, Anum Shaukat, Rameez Cureus Gastroenterology Drug-induced acute pancreatitis (DIAP) is a rare gastrointestinal condition but well-known in the medical literature. The medications have been classified into four subgroups (Classes I-IV) depending upon the propensity of the cases discussed in the literature, interval time period between drug initiation to pancreatitis, and reaction to the drug with reintroduction. Our clinical case is one such example where losartan was described as the agent of recurrent pancreatitis after excluding all other possible causes with laboratory and imaging studies. Cureus 2019-11-28 /pmc/articles/PMC6937474/ /pubmed/31893179 http://dx.doi.org/10.7759/cureus.6253 Text en Copyright © 2019, Anwar et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Gastroenterology
Anwar, Shamsuddin M
Aqsa, Anum
Shaukat, Rameez
Losartan-induced Pancreatitis
title Losartan-induced Pancreatitis
title_full Losartan-induced Pancreatitis
title_fullStr Losartan-induced Pancreatitis
title_full_unstemmed Losartan-induced Pancreatitis
title_short Losartan-induced Pancreatitis
title_sort losartan-induced pancreatitis
topic Gastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937474/
https://www.ncbi.nlm.nih.gov/pubmed/31893179
http://dx.doi.org/10.7759/cureus.6253
work_keys_str_mv AT anwarshamsuddinm losartaninducedpancreatitis
AT aqsaanum losartaninducedpancreatitis
AT shaukatrameez losartaninducedpancreatitis